SCHEDULE 13G/A: Ameriprise Financial and Affiliates Disclose Updated Passive Stake in Altimmune, Inc.

Ameriprise Financial, Inc. and its affiliated entities have filed an amended Schedule 13G, disclosing their beneficial ownership of Altimmune, Inc. common stock as of March 31, 2025.

Summary

• Ameriprise Financial, Inc. and its subsidiaries, including TAM UK International Holdings Limited, Threadneedle Holdings Limited, and others (collectively, 'Ameriprise Entities'), have filed an Amendment No. 3 to Schedule 13G.
• The filing reports beneficial ownership of common stock in Altimmune, Inc. (CUSIP: 02155H200).
• As of March 31, 2025, Ameriprise Financial, Inc. beneficially owns an aggregate of 1,443,932 shares, representing 1.9% of Altimmune, Inc.'s common stock.
• The Ameriprise Entities, such as TAM UK International Holdings Limited and Threadneedle Asset Management Limited, each report beneficial ownership of 1,324,639 shares, representing 1.7% of the class.
• Ameriprise Financial, Inc., as the parent company, includes the shares reported by its subsidiaries in its aggregate beneficial ownership.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, providing neutral information without explicit positive or negative performance indicators or forward-looking statements.

Positives

• The filing demonstrates continued institutional interest in Altimmune, Inc. by a major financial entity, Ameriprise Financial, Inc. and its affiliates.
• The disclosure provides transparency regarding significant passive ownership stakes, which is beneficial for market participants.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of passive institutional ownership, common in the financial industry where large asset managers hold stakes in publicly traded companies for investment purposes. It reflects a standard practice of transparency required by SEC regulations for significant shareholders.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional holdings, which can offer insights into institutional confidence in the company.
• Investors: Offers data on the ownership structure of Altimmune, Inc., which can be a factor in investment decisions.

Key Dates

Keywords

Altimmune Inc., Ameriprise Financial, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Investment Management, Financial Services